Handelsbanken Fonder AB Sells 6,529 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Handelsbanken Fonder AB lessened its position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 23.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,280 shares of the company's stock after selling 6,529 shares during the quarter. Handelsbanken Fonder AB's holdings in BeiGene were worth $3,838,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Toronto Dominion Bank lifted its position in shares of BeiGene by 166.4% during the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company's stock worth $60,000 after buying an additional 208 shares during the period. Knights of Columbus Asset Advisors LLC lifted its position in shares of BeiGene by 20.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company's stock worth $80,000 after buying an additional 76 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of BeiGene by 123.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 732 shares of the company's stock worth $132,000 after buying an additional 405 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of BeiGene by 98.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,078 shares of the company's stock worth $194,000 after buying an additional 536 shares during the period. Finally, Clear Harbor Asset Management LLC bought a new position in shares of BeiGene during the 4th quarter worth approximately $208,000. Institutional investors and hedge funds own 48.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BGNE shares. TD Cowen raised their target price on BeiGene from $235.00 to $236.00 and gave the stock a "buy" rating in a research report on Wednesday. Bank of America cut their price objective on BeiGene from $179.30 to $164.30 and set a "neutral" rating for the company in a research report on Monday, April 8th. JPMorgan Chase & Co. lifted their price objective on BeiGene from $184.00 to $186.00 and gave the company an "overweight" rating in a research report on Tuesday, March 19th. Guggenheim cut their price objective on BeiGene from $350.00 to $345.00 and set a "buy" rating for the company in a research report on Tuesday, February 27th. Finally, Sanford C. Bernstein cut their price objective on BeiGene from $196.00 to $161.00 and set a "market perform" rating for the company in a research report on Wednesday, March 27th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $250.13.

Insider Buying and Selling

In related news, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total transaction of $66,330.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of the business's stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Oyler sold 26,716 shares of the business's stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24. Following the completion of the transaction, the chief executive officer now directly owns 12,084 shares of the company's stock, valued at $1,799,186.76. The disclosure for this sale can be found here. Insiders sold a total of 64,781 shares of company stock valued at $10,222,381 over the last three months. Company insiders own 7.40% of the company's stock.

BeiGene Stock Performance

Shares of NASDAQ BGNE traded up $5.02 during midday trading on Friday, hitting $153.58. The stock had a trading volume of 208,460 shares, compared to its average volume of 258,702. The company's 50-day simple moving average is $154.73 and its 200 day simple moving average is $167.40. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $266.67. The company has a quick ratio of 2.09, a current ratio of 2.32 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE - Get Free Report) last announced its quarterly earnings data on Monday, February 26th. The company reported ($3.53) EPS for the quarter, topping analysts' consensus estimates of ($3.61) by $0.08. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The business had revenue of $634.40 million during the quarter, compared to analysts' expectations of $632.52 million. During the same period in the previous year, the firm earned ($4.29) earnings per share. The firm's quarterly revenue was up 66.9% compared to the same quarter last year. Equities analysts anticipate that BeiGene, Ltd. will post -8.87 earnings per share for the current year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.